A Study of Mammographic Breast Density For Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Logo Image
"Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!"
Age: -1 years or older
Gender:
Female
Healthy Volunteers: No
Keywords: breast cancer, Hormone Receptor-Negative Breast Cancer, extension study
Type: Procedure study
Target:
5 Participants
Investigator:
Description
This study is being done as a companion study to the Alliance A011502 clinical trial. The purpose of this study is to see if the use of aspirin causes a decrease in mammographic breast density.

The breast is composed of fat, milk glands and various other tissues. These determine how dense the breasts are. High breast density has been shown to be a strong risk factor for developing breast cancer. It is thought that decreasing breast density may decrease the risk for breast cancer. The main goal of this study is to see whether women treated with aspirin will have reduced breast density as seen on a mammogram. Breast density is determined by a mammogram, and cannot be determined by a physical exam.
This study requires

The study team will make sure you qualify to take part in the study. Qualified participants will receive detailed information about the study. This may include a list of study-related tests and procedures.

Who can participate

Eligibility Criteria

Patients must be women concurrently enrolling to Alliance A011502.

Eligible patients may be either pre- or post-menopausal.

Patients must have hormone receptor-negative breast cancer.

Patients must have baseline breast density measurement as defined by one of the following: 1) ≥ 25% breast density, or 2) scattered areas of fibroglandular density, or 3) breast composition category b, c, or d, per BI-RADS 2013

Baseline digital mammogram with at least a mediolateral (MLO) and a craniocaudal (CC) view taken prior to all cancer treatment and within 8 weeks prior to registration must be available for submission.

Patients receiving endocrine therapy (e.g., tamoxifen, aromatase inhibitors) are not eligible.

Contralateral unaffected breast in place (with no prior cancer or radiation, no implants and no plan for breast surgery on contralateral breast over the course of the study). Patients with a prior biopsy on the unaffected breast are eligible.

Benefits and risks of participating
BENEFITS:

We cannot promise any benefits to you as a result of taking part in this research study.


RISKS:

The study doctor will discuss the risks associated with taking part in this research study.
Compensation
You will not be paid to take part in this research study.
Resources
Schedule
Study duration and period
You will be in the study for at least 2 years. During this time, we will need: • Mammograms closest to year 1 after you started that study. • Mammograms closest to year 2 after you started that study.
Recruitment period
From Oct. 22, 2018
Location
UC Davis Comprehensive Cancer Center
4501 X Street
Sacramento, CA 95817
Research Topic
Conditions:
  • Breast Carcinoma
  • Estrogen Receptor Negative
  • Progesterone Receptor Negative

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Sending

Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:


E-mail Preview